Search Result

Results for "

PARP-1-IN-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (10) Autophagy (1) c-Met/HGFR (1) Caspase (1) CDK (1) DNA/RNA Synthesis (2) E3 Ligase Ligand-Linker Conjugates (1) HDAC (1) Histone Methyltransferase (1) HyT (1) Isotope-Labeled Compounds (1) Ligands for E3 Ligase (1) Microtubule/Tubulin (2) NAMPT (1) Necroptosis (1) PANoptosis (1) PARP (32) PI3K (1) PROTACs (1) Pyroptosis (1) Pyruvate Kinase (1) Reactive Oxygen Species (ROS) (1) Reference Standards (3) Topoisomerase (1) VEGFR (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (33) Inflammation/Immunology (2) Neurological Disease (2)

By Targets:

Apoptosis (10)

Autophagy (1)

c-Met/HGFR (1)

Caspase (1)

CDK (1)

DNA/RNA Synthesis (2)

E3 Ligase Ligand-Linker Conjugates (1)

HDAC (1)

Histone Methyltransferase (1)

HyT (1)

Isotope-Labeled Compounds (1)

Ligands for E3 Ligase (1)

Microtubule/Tubulin (2)

NAMPT (1)

Necroptosis (1)

PANoptosis (1)

PARP (32)

PI3K (1)

PROTACs (1)

Pyroptosis (1)

Pyruvate Kinase (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (3)

Topoisomerase (1)

VEGFR (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (33)

Inflammation/Immunology (2)

Neurological Disease (2)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10617A

Rucaparib Maximum Cited Publications 47 Publications Verification AG014699; PF-01367338	PARP	Cancer
Rucaparib (AG014699) is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617

Rucaparib phosphate 45+ Cited Publications AG-014699 phosphate; PF-01367338 phosphate	PARP	Cancer
Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-12418

Stenoparib 2 Publications Verification E7449; 2X-121	PARP	Cancer
Stenoparib (E7449) is a potent *PARP1* and *PARP2* inhibitor and also inhibits TNKS1 and TNKS2, with IC₅₀s of 2.0, 1.0, ～50 and ～50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using ³²P-NAD ⁺ as substrate.

HY-102003

Rucaparib monocamsylate 35+ Cited Publications AG014699 monocamsylate; PF-01367338 monocamsylate	PARP	Cancer
Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-13536

AZD-2461 5+ Cited Publications	PARP	Cancer
AZD-2461 is a potent *PARP* inhibitor, with IC₅₀s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.

HY-12975

AZ6102 3 Publications Verification	PARP	Cancer
AZ6102 is a potent dual TNKS1 and TNKS2 inhibitor, with IC₅₀s of 3 nM and 1 nM, respectively, and alao has 100-fold selectivity against other PARP family enzymes, with IC₅₀s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PARP6, respectively.

HY-147027

*PARP-1-IN-2*	PARP Caspase Apoptosis	Neurological Disease Inflammation/Immunology Cancer
PARP-1-IN-2 (compound 11g) is a potent *PARP1* inhibitor, with an IC₅₀ of 149 nM, and ADME prediction indicates it has high blood-brain barrier permeability. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis .

HY-119653

AZ9482	PARP	Cancer
AZ9482 is a triple *PARP1/2/6* inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

HY-146336

PARP1/2/TNKS1/2-IN-1	PARP Apoptosis	Cancer
PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual *PARP-1, PARP-2*, TNKS1 and TNKS2 inhibitor with IC₅₀ values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis .

HY-102003A

Rucaparib camsylate AG014699 camsylate; PF-01367338 camsylate	PARP	Cancer
Rucaparib (AG014699) camsylate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib camsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib camsylate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-133124

PARP/PI3K-IN-1	PARP PI3K Apoptosis	Cancer
PARP/PI3K-IN-1 (compound 15) is a potent *PARP/PI3K* inhibitor with pIC₅₀ values of 8.22, 8.44, 8.25, 6.54, 8.13, 6.08 for PARP-1, PARP-2, PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively. PARP/PI3K-IN-1 is a highly effective anticancer compound targeted against a wide range of oncologic diseases .

HY-179386

PARP1/EZH2-IN-1	PARP Histone Methyltransferase Apoptosis Pyroptosis Necroptosis Reactive Oxygen Species (ROS) PANoptosis	Cancer
PARP1/EZH2-IN-1 is a selective *PARP1* and EZH2 dual inhibitor. PARP1/EZH2-IN-1 has IC₅₀s of 28 nM, 414 nM and 74 nM for *PARP1, PARP2* and EZH2, respectively. PARP1/EZH2-IN-1 inhibits the proliferation and migration of TNBC cells (triple-negative breast Cancer cells). PARP1/EZH2-IN-1 induces PANoptosis (Apoptosis, Pyroptosis and Necroptosis), increases the level of reactive oxygen species (ROS), and activates related inflammatory pathways. PARP1/EZH2-IN-1 can be used in triple-negative breast cancer research .

HY-170972

PARP1/NAMPT-IN-2	Apoptosis PARP NAMPT	Cancer
PARP1/NAMPT-IN-2 (Compound 13j) is a dual *PARP/NAMPT* inhibitor with IC₅₀ values of 0.8 nM and 18 nM for *PARP1* and NAMPT, respectively. PARP1/NAMPT-IN-2 can inhibit the proliferation, migration and induce apoptosis of breast cancer cells. PARP1/NAMPT-IN-2 can be used for the research of triple-negative breast cancer .

HY-164306

PROTAC PARP1 degrader-2	PROTACs PARP	Cancer
PROTAC PARP1 degrader-2 (Compound 72) is a PROTAC degrader for *PARP* with a DC₅₀<10 nM in MDA-MB-231 cell. PROTAC PARP1 degrader-2 inhibits the cell viability of MDA-MB-436 with an IC₅₀ <100 nM. (Blue: ligand for target protein (HY-160937); Pink: ligand for E3 ligase (HY-W998262))

HY-157490

PARP/HDAC-IN-1	PARP HDAC	Cancer
PARP/HDAC-IN-1 (compound B102) is a potent dual inhibitor of *PARP* and HDAC. PARP/HDAC-IN-1 inhibits *PARP1, PARP2* and HDAC1 with IC₅₀s of 19.01, 2.13, 1690 nM, respectively .

HY-169299

TOPOI/PARP-1-IN-2	PARP Topoisomerase Apoptosis	Cancer
TOPOI/PARP-1-IN-2 (compound 6c) is a dual *PARP-1* and topoisomerase 1 (TOPO-1) inhibitor with IC₅₀s of 32.2 nM and 46.2 nM, respectively. TOPOI/PARP-1-IN-2 shows a selectivity for PARP-1 over PARP-2. TOPOI/PARP-1-IN-2 disrupts the cell cycle at the S phase and induces apoptosis in NCI-60 cancer cell lines .

HY-10617B

Rucaparib hydrochloride AG014699 hydrochloride; PF-01367338 hydrochloride	PARP	Cancer
Rucaparib (AG014699) hydrochloride is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib hydrochloride is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib hydrochloride has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617C

Rucaparib tartrate AG-014699 tartrate; PF-01367338 tartrate	PARP	Cancer
Rucaparib (AG014699) tartrate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib tartrate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib tartrate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617AR

Rucaparib (Standard) AG014699 (Standard); PF-01367338 (Standard)	Reference Standards PARP	Cancer
Rucaparib (Standard) is the analytical standard of Rucaparib. This product is intended for research and analytical applications. Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

HY-100847

AZ0108	PARP	Cancer
AZ0108 is an inhibitor for poly ADP-ribose polymerase (PARP), which inhibits PARP1, PARP2, PARP3, PARP6, TNKS1, TNKS2, with IC₅₀s of <0.03, <0.03, 2.8, 0.083, 3.2, >3 μM, respectively. AZ0108 prevents centrosome clustering with an EC₅₀ of 0.053 μM, and exhibits cytotoxicity in cell OCI-LY-19 with GI₅₀ of 0.017 μM. AZ0108 exhibits good in vivo pharmacokinetic characters in rat/mouse models .

HY-178348

PARP1/c-Met-IN-2	PARP c-Met/HGFR DNA/RNA Synthesis	Cancer
PARP1/c-Met-IN-2 is a highly potent, orally active, *PARP1* (IC₅₀ = 21.8 nM) and c-Met (IC₅₀ = 30.2 nM) dual inhibitor. PARP1/c-Met-IN-2 can elevate the expression level of γH2AX, cause DNA damage. PARP1/c-Met-IN-2 exhibits remarkable anti-tumor efficacy in the Olaparib (HY-10162)-resistant HCT116 (HCT116OR) xenograft models. PARP1/c-Met-IN-2 can be used for the study of Colon Cancer .

HY-15050

KCL-440	PARP	Neurological Disease Inflammation/Immunology
KCL-440 is a CNS-penetrated *PARP* inhibitor, with an IC₅₀ of 68 nM. KCL-440 has strong inhibition of PARP-1 .

HY-W998262

Pomalidomide 5-piperidylamine	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide 5-piperidylamine is the conjugate of an E3 ligase ligand and a linker. Pomalidomide 5-piperidylamine can be used for synthesis of PROTAC PARP1 degrader-2 (HY-164306) .

HY-10617D

Rucaparib acetate AG014699 acetate; PF-01367338 acetate	PARP	Cancer
Rucaparib (AG014699) acetate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib acetate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib acetate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-168851

PARP1-IN-35	PARP	Cancer
PARP1-IN-35 (compound T26) is a selective, orally active, cross -the blood-brain barrierPARP1 inhibitor with IC₅₀ values of 0.2, 122 nM for PARP1, PARP2, respectively. PARP1-IN-35 shows antiproliferative activity and anticancer activity. PARP1-IN-35 has the potential for the research of breast cancer .

HY-157320

*Tubulin/PARP-IN-2*	Microtubule/Tubulin Apoptosis	Cancer
Tubulin/PARP-IN-2 (compound 14) is a dual *PARP-Tubulin* inhibitor. Tubulin/PARP-IN-2 inhibits PARP1, PARP2, and tubulin activity with IC₅₀ values of 74 nM, 109 nM, and 1.4 µM, respectively. Tubulin/PARP-IN-2 induces apoptosis as well as autophagy. Tubulin/PARP-IN-2 causes cell cycle arrest at the G2/M phase .

HY-10617R

Rucaparib phosphate (Standard) AG-014699 phosphate (Standard); PF-01367338 phosphate (Standard)	Reference Standards PARP	Cancer
Rucaparib (phosphate) (Standard) is the analytical standard of Rucaparib (phosphate). This product is intended for research and analytical applications. Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-176713

KWZY-11	PARP CDK Wnt β-catenin Apoptosis	Cancer
KWZY-11 (Compound 11) is a potent *PARP/CDK6* dual inhibitor with IC₅₀ values of 156.8, 197.3, and 13.3 nM for PARP1, PARP2, and CDK6, respectively. KWZY-11 inhibits tumor cell proliferation by regulating the Wnt/β-catenin signaling pathway. KWZY-11 induces excessive DNA damage and apoptosis in MDA-MB-231 breast cancer cells .

HY-10617AS

Rucaparib-d8 AG014699-d₈ ; PF-01367338-d₈	Isotope-Labeled Compounds PARP	Cancer
Rucaparib-d₈ (AG014699-d₈ ) is deuterium labeled Rucaparib. Rucaparib (AG014699) is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

HY-179020

PARP/VEGFR3-IN-1	PARP VEGFR DNA/RNA Synthesis Apoptosis Autophagy	Cancer
PARP/VEGFR3-IN-1 (Compound 18) is a dual PARP-VEGFR3 target inhibitor. Its IC₅₀ values for PARP1, PARP2, and VEGFR3 are 0.0763, 0.0366, and 4.25 nM respectively. PARP/VEGFR3-IN-1 has no inhibitory effect on VEGFR1/2 and shows subtype selectivity. PARP/VEGFR3-IN-1 exhibits significant anti-proliferative activity in various cancer cells (leukemia, lung cancer, and triple-negative breast cancer). PARP/VEGFR3-IN-1 induces DNA damage and cell cycle arrest. PARP/VEGFR3-IN-1 triggers various forms of cell death by inducing apoptosis and autophagy. PARP/VEGFR3-IN-1 can be formulated into nanodelivery systems, significantly enhancing tumor targeting and therapeutic window .

HY-183765

PARP1/PKM2-IN-1	PARP Pyruvate Kinase	Cancer
PARP1/PKM2-IN-1 is a dual *PARP1/PKM2* inhibitor, with an IC₅₀ of 39.5 nM against *PARP1, and IC₅₀* values of 261 nM (recombinant PKM2) and 50 nM (dimeric PKM2) against PKM2. PARP1/PKM2-IN-1 reduces the dimerization of PKM2 and decreases its nuclear accumulation level. PARP1/PKM2-IN-1 also selectively downregulates PKM2 mRNA and impairs poly (ADP-ribose)-mediated nuclear retention of PKM2. PARP1/PKM2-IN-1 exhibits antiproliferative activity and inhibits the formation of 3D cancer spheroids. PARP1/PKM2-IN-1 can be used in research related to mammary adenocarcinoma, triple-negative breast cancer, BRCA1-mutant triple-negative breast cancer, and prostate adenocarcinoma .

HY-181460

*PARP1 degrader-2*	HyT PARP	Cancer
PARP1 degrader-2 (Compound 11e) is a potent, selective *PARP1* HYT degrader (DC₅₀: 2.16 μM). PARP1 degrader-2 selectively binds to and degrades PARP1 but not PARP2. PARP1 degrader-2 mediates the degradation of PARP1 via the ubiquitin-proteasome system (UPS). PARP1 degrader-2 exhibits anticancer activity against triple-negative breast cancer and colon cancer (hydrophobic tag: (HY-W022007); PARP1 ligand: (HY-75706); Linker: (HY-W015300)) .

HY-W022007

5-Norbornene-2-methylamine JBP	Ligands for E3 Ligase	Others
5-Norbornene-2-methylamine (JBP) is a hydrophobic tag. 5-Norbornene-2-methylamine can be used for the synthesis of HyT degraders, such as PARP1 degrader-2 (HY-181460) .

HY-181068

2'-Nitroflavone	PARP Apoptosis Microtubule/Tubulin	Cancer
2'-Nitroflavone is a *PARP1* inhibitor. 2'-Nitroflavone inhibits the proliferation, induces cell cycle arrest and apoptosis of triple-negative breast cancer cells. 2'-Nitroflavone also inhibits the migration of triple-negative breast cancer cells and endothelial cells. 2'-Nitroflavone exhibits antitumor activity and can be used in the research of tumors such as triple-negative breast cancer .

HY-102003R

Rucaparib monocamsylate (Standard) AG014699 monocamsylate (Standard); PF-01367338 monocamsylate (Standard)	Reference Standards PARP	Cancer
Rucaparib monocamsylate (Standard) is the analytical standard of Rucaparib monocamsylate (HY-102003). This product is intended for research and analytical applications. Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research .

Cat. No.	Product Name	Chemical Structure

HY-10617AS

Rucaparib-d8
Rucaparib-d₈ (AG014699-d₈ ) is deuterium labeled Rucaparib. Rucaparib (AG014699) is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: